Sanofi Says Sutimlimab Meets Endpoint in Phase 3 Trial

Date : 11/21/2019 @ 3:25PM
Source : Dow Jones News
Stock : Sanofi (SNY)
Quote : 49.79  0.28 (0.57%) @ 1:00AM
After Hours
Last Trade
Last $ 49.79 ◊ 0.00 (0.00%)

Sanofi Says Sutimlimab Meets Endpoint in Phase 3 Trial

Sanofi (NASDAQ:SNY)
Historical Stock Chart

1 Month : From Nov 2019 to Dec 2019

Click Here for more Sanofi Charts.

By Michael Dabaie

 

Sanofi (SNY) said sutimlimab met its primary efficacy endpoint in a Phase 3 trial for patients with cold agglutinin disease.

CAD is a severe and chronic rare blood disorder in which the immune system mistakenly attacks a person's own healthy red blood cells. There are currently no approved treatments, Sanofi said.

A total of 24 patients were enrolled; two withdrew from the study for non-drug related reasons. All 22 patients that completed Part A of the study have enrolled in an ongoing long-term follow-up study.

The primary efficacy outcome was response rate based on a composite of an increase in hemoglobin from baseline or reaching a hemoglobin level at treatment assessment endpoint and the absence of transfusions between weeks 5 to 26.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

November 21, 2019 10:10 ET (15:10 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest SNY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.